We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00175435
First Posted: September 15, 2005
Last Update Posted: November 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of British Columbia
  Purpose
This study will look at what happens to the level of protection against hepatitis B (HB) disease if a 'helper' gel is applied to the skin over the injection site of a small dose of hepatitis B vaccine.

Condition Intervention Phase
Hepatitis B Biological: Resiquimod gel Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

Resource links provided by NLM:


Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • A single application of an immune modulating gel will enhance the protective response against hepatitis B disease when vaccination is given at the same time as gel as evidenced by increased HB antibody and T-cell response. [ Time Frame: at 30 days after vaccination ]

Secondary Outcome Measures:
  • Minimal adverse effects to gel application as noted by laboratory assessment of liver enzyme and complete blood count (CBC) and physical assessment of the site/surrounding area and solicited local and general post vaccine events. [ Time Frame: at 7 and 30 days post vaccine ]

Enrollment: 39
Study Start Date: August 2005
Study Completion Date: April 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
Biological: Resiquimod gel
3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
Other Name: HPV vaccine - Gardasil
Active Comparator: 2
3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
Biological: Resiquimod gel
3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
Other Name: HPV vaccine = Gardasil
Active Comparator: 3
3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
Biological: Resiquimod gel
3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
Other Name: HPV vaccine = Gardasil

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Previously vaccinated with conventional hepatitis B vaccine series 10 or more years ago
  • Generally healthy
  • Is and has been free of HB disease and/or is negative to core antibody
  • Known to have sero-converted to positive after vaccine series (without extra doses)
  • Speaks and understands English adequately
  • Available for all 4 visits within the designated timelines (30 days)
  • No allergies to HB vaccine or components
  • No blood or blood components within previous 6 months
  • Not pregnant or breastfeeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00175435


Locations
Canada, British Columbia
Vancouver General Hospital Vaccine Education Centre
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Jan Dutz, MD University of British Columbia
  More Information

Responsible Party: Dr. Jan Dutz, University of British Columbia
ClinicalTrials.gov Identifier: NCT00175435     History of Changes
Other Study ID Numbers: C05-0027
First Submitted: September 11, 2005
First Posted: September 15, 2005
Last Update Posted: November 2, 2010
Last Verified: October 2010

Keywords provided by University of British Columbia:
Topical Immune Modulator
resiquimod gel
Hepatitis B booster response
Vaccine Evaluation
Prevention of Hepatitis B disease

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs


To Top